TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00933751

Intervention type: DEVICE
Intervention: Central vein catheterization
Description: Blood samplings from IVC catheter
Study: NCT00282256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus modified release (MR)
Description: Oral
Study: NCT02103309

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lenses
Study: NCT00282256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral
Study: NCT05031728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Description: Cognitive processing therapy (CPT) (Resick et al., 2016) which is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of Post-Traumatic Stress Disorder (PTSD) that may have developed after experiencing a variety of traumatic events including child abuse, emotional abuse, combat, rape war, and natural disasters. CPT helps patients learn how to challenge and modify unhelpful beliefs related to the trauma and emotional pain. In so doing, the client creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life.
Study: NCT06203314

Intervention type: OTHER
Intervention: Diagnostic test: EBV antibody tests
Description: Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.

Intervention type: OTHER
Intervention: Diagnostic test: EBV antibody tests
Description: Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
Study: NCT02728037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnesium-Based Injection Formulation
Description: Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the magnesium-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 50% magnesium sulfate, 2) 20ml of 8.4% bicarbonate, and 3) 20ml of 50% dextrose.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine, 0.8% sodium bicarbonate, 6.0% dextrose, and 2.5% magnesium sulfate.
Study: NCT02654548

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sebutape
Description: Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sebutape
Description: Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
Study: NCT03026699

Intervention type: BEHAVIORAL
Intervention: eSNAP
Description: Participants in the intervention group will then be given a tablet loaded with the eSNAP application and asked to create a visualization of their social networks. Upon completion, participants will be asked to review their ecomaps and complete the user experience questionnaire.

Intervention type: BEHAVIORAL
Intervention: eSNAP
Description: Participants in the intervention group will then be given a tablet loaded with the eSNAP application and asked to create a visualization of their social networks. Upon completion, participants will be asked to review their ecomaps and complete the user experience questionnaire.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will complete demographics and baseline (T1; baseline) questionnaires. For all participants Time 2 (T2; 3 week) and Time 3 (T3; 6 week) questionnaires will be completed either by phone, mail, or email (depending on participant preference) to assess longer-term effects of eSNAP on outcomes versus controls.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will complete demographics and baseline (T1; baseline) questionnaires. For all participants Time 2 (T2; 3 week) and Time 3 (T3; 6 week) questionnaires will be completed either by phone, mail, or email (depending on participant preference) to assess longer-term effects of eSNAP on outcomes versus controls.
Study: NCT02728037

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-Only Injection Formulation
Description: Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the lidocaine-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 0.9% sodium chloride, 2) 20ml of 0.9% sodium chloride, and 3) 20ml of 0.9% sodium chloride.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Study: NCT03026699

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will complete demographics and baseline (T1; baseline) questionnaires. For all participants Time 2 (T2; 3 week) and Time 3 (T3; 6 week) questionnaires will be completed either by phone, mail, or email (depending on participant preference) to assess longer-term effects of eSNAP on outcomes versus controls.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will complete demographics and baseline (T1; baseline) questionnaires. For all participants Time 2 (T2; 3 week) and Time 3 (T3; 6 week) questionnaires will be completed either by phone, mail, or email (depending on participant preference) to assess longer-term effects of eSNAP on outcomes versus controls.
Study: NCT01253291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered subcutaneously every 4 weeks for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered subcutaneously every 4 weeks for 48 weeks
Study: NCT00950586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1043702
Description: Oral dose in liquid or tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1043702
Description: Oral dose in liquid or tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1043702
Description: Oral dose in liquid or tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 30mg Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To match GSK1034702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To match GSK1034702
Study: NCT02907151

Intervention type: OTHER
Intervention: Survey
Description: Complete a survey prior to the consultation and a questionnaire after
Study: NCT00880620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 95 mg LD
Description: IPX066 capsule containing 95 mg LD/23.75 mg CD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 95 mg LD
Description: IPX066 capsule containing 95 mg LD/23.75 mg CD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 95 mg LD
Description: IPX066 capsule containing 95 mg LD/23.75 mg CD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 145 mg LD
Description: IPX066 capsule containing 145 mg LD/36.25 mg CD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 145 mg LD
Description: IPX066 capsule containing 145 mg LD/36.25 mg CD
Study: NCT02728037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Study: NCT00880620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 145 mg LD
Description: IPX066 capsule containing 145 mg LD/36.25 mg CD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 195 mg LD
Description: IPX066 capsule containing 195 mg LD/48.75 mg CD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 195 mg LD
Description: IPX066 capsule containing 195 mg LD/48.75 mg CD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 245 mg LD
Description: IPX066 capsule containing 245 mg LD/61.25 mg CD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 245 mg LD
Description: IPX066 capsule containing 245 mg LD/61.25 mg CD
Study: NCT02108249

Intervention type: DEVICE
Intervention: Annex™ Adjacent Level System
Study: NCT00951366

Intervention type: OTHER
Intervention: Patient Registry
Description: The CHILD Clinic Patient Registry is an observational study designed to identify epidemiologic and genetic factors associated with chronic lung disease in former preterm infants or those with lung disease in the neonatal period.
Study: NCT05899439

Intervention type: OTHER
Intervention: blood draw
Description: a peripheral blood draw

Intervention type: OTHER
Intervention: blood draw
Description: a peripheral blood draw
Study: NCT06443372

Intervention type: OTHER
Intervention: Clinical periodontal measurements, GCF sampling
Description: Clinical periodontal measuements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF samples were obtained 1 day following the clinical measurements. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis.

Intervention type: OTHER
Intervention: Clinical periodontal measurements, GCF sampling
Description: Clinical periodontal measuements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF samples were obtained 1 day following the clinical measurements. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis.

Intervention type: OTHER
Intervention: Clinical periodontal measurements, GCF sampling
Description: Clinical periodontal measuements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF samples were obtained 1 day following the clinical measurements. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis.
Study: NCT03416140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: 30 minutes per day of therapeutic exercise
Study: NCT03549221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6 mg 1:1000 epinephrine (0.6 ml)
Description: In group 1, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). In group 2, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). Both groups were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
Study: NCT02210728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate or amphetamine product
Description: Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate or amphetamine product
Description: Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
Study: NCT02728037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulfate, bicarbonate, dextrose.
Study: NCT03759821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition, mothers
Description: Nutrition-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition, mothers and fathers
Description: Nutrition-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition+parenting, mothers
Description: Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition+parenting, mothers and fathers
Description: Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
Study: NCT03576391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control condition
Description: 45 minute rest while seated. Watching an animated movie, sleeping was not allowed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid Arm Movements
Description: 2 blocks of 80 trials of RAM in either a forward (n = 40) or backward (n = 40) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
Study: NCT02210728

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: 12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: 12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.
Study: NCT03641937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00011
Description: INVSENSOR00011 - investigational sensor that will be placed on the subject's chest and/or back for the duration of the study.
Study: NCT03852134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MOCC Group
Description: After 30 seconds of DCC, the cord will be clamped and cut 5 cm from the introitus in vaginal delivery or abdominal incision in the case of cesarean section before passing the infant with the long umbilical cord segment to the pediatric provider who will milk the cord one time towards the baby during resuscitation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCC Group
Description: The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines.
Study: NCT03043885

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDBA
Description: Graft material used to graft extraction socket

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDBA
Description: Graft material used to graft extraction socket

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRF
Description: Autologous blood product used to graft extraction socket

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRF
Description: Autologous blood product used to graft extraction socket

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Clot
Description: Surgical treatment of extraction socket without addition of graft material
Study: NCT04071197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastostomy-biliary tube
Description: gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External biliary diversion, internal biliary diversion and nasobiliary tube
Description: All biliary diversion modalities other than gastrobiliary tube
Study: NCT00950586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To match GSK1034702
Study: NCT03164811

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: goal directed fluid therapy
Description: pulse pressure variation will be used to as a goal to guide fluid administration in this group

Intervention type: OTHER
Group type: OTHER
Intervention: Controlled
Description: standard fluid treatment by an anesthesiologist
Study: NCT03553758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Subjects' brain waves will be monitored by EEG recording under ketamine general anesthesia over the course of approximately 60 minutes. Patients pain and dissociation will be assessed before the induction of ketamine and periodically after. Approximately 1 hour after ketamine induction, Midazolam will be administered to reduce patient dissociation.
Study: NCT03210207

Intervention type: PROCEDURE
Intervention: GASTROPLICATURE
Description: All procedures were performed by a single surgeon. All patients underwent 2-row gastric plication. Dissection was started at the greater curvature of the stomach in contact to the gastric wall from prepyloric area to 2-cm proximal to the Hiss angle preserving the anatomy of Hiss angle. All vessels along the greater curvature were separated using LigaSure (Covidien, Mansfield, MA, USA). The greater curvature (from the perimeter) was invaginated using 2 rows of 00 prolene or 00 nylon sutures. Two layers of plication were performed with continuous sutures with 1 surgical sting in all patients to prevent any displacement of inverted folds such as eversion outside or intussusception into esophagus or pylorus. All sutures were extramucusal to avoid their absorption by gastric acid. Finally, a tube shaped stomach was achieved in which the greater curvature was inverted in to the stomach.
Study: NCT04657471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: revised HOME-CoV score
Description: Educational lectures, posters, and pocket cards showing and explaining the revised HOME-CoV score are communicated to participating Emergency Departments.~For included patients, the physician-in-charge calculates the revised HOME-CoV. Patients with a score \<2 qualified for home treatment. They qualified otherwise for hospitalization. For patients with a score \> 4, hospitalization in a unit allowing monitoring of vital parameters is recommended. However, the physician-in-charge can overrule the qualification for home treatment or for hospitalization in case of major medical or social reasons. A justification explaining the cause of overruling is required.
Study: NCT04260893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel
Description: Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
Study: NCT00239239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: darbepoetin alfa SC dosing 0.45 mcg/kg 3 times per week through study day 40. Optional extended treatment period: 200 mcg Q2W through study day 110
Study: NCT02448277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh Laryngoscope
Description: the device is to assist nasotracheal intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pentax Airway scope
Description: the device is to assist the nasotracheal tube into trachea

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope
Description: the device is to assist the nasotracheal tube into trachea
Study: NCT01847300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cSBI-M
Description: In cSBI-M participants complete a computerized screen for alcohol and tobacco use and then view 10 pages describing the health effects of substance use and true life stories of those affected by substance use.